Efficacy of ribavirin monotherapy following combination therapy with interferon alfa-2b and ribavirin for patients with chronic hepatitis C

Hepatology Research

Volumn 32, Issue 2, 2005, Pages 101-106

  Nagayama, Ryozo ^a   Tanaka, Atsushi ^a,e   Ankoh, Haruhiro ^b   Narita, Tohru ^c   Izumi, Masaki ^d   Miyake, Kazuhiko ^a   Takikawa, Hajime ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Ganstroenterology   (Japan)

^c Akabane Central Hospital   (Japan)

^d Tokyo Musashino Hospital   (Japan)

^e TEIKYO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Interferon alfa; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TOXICITY; LONG TERM CARE; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT OUTCOME; VIRUS LOAD;

EID: 21744453692     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2005.02.007     Document Type: Article

References (17)

1. J. McHutchison S. Gordon E. Schiff M. Shiffman W. Lee V. Rustgi et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1485-1492
2. T. Poynard P. Marcellin S. Lee C. Niederau G. Minuk G. Ideo et al. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 1998 1426-1432
3. G. Davis R. Esteban-Mur V. Rustgi J. Hoefs S. Gordon C. Trepo et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1493-1499
4. A. Di Bisceglie H. Conjeevaram M. Fried R. Sallie Y. Park C. Yurdaydin et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial Ann Intern Med 123 1995 897-903
5. G. Dusheiko J. Main H. Thomas O. Reichard C. Lee A. Dhillon et al. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study J Hepatol 25 1996 591-598
6. H.J. Bodenheimer K. Lindsay G. Davis J. Lewis S. Thung L. Seeff Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial Hepatology 26 1997 473-477
7. J. Patterson R. Fernandez-Larsson Molecular mechanisms of action of ribavirin Rev Infect Dis 12 1990 1139-1146
8. J. Hoofnagle D. Lau H. Conjeevaram D. Kleiner A. Di Bisceglie Prolonged therapy of chronic hepatitis C with ribavirin J Viral Hepatol 3 1996 247-252
9. E. Ueda N. Enomoto N. Sakamoto K. Hamano C. Sato N. Izumi et al. Changes of HCV quasispecies during combination therapy with interferon and ribavirin Hepatol Res 29 2004 89-96
10. M. Shiffman C. Hofmann R. Sterling V. Luketic M. Contos A. Sanyal A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response J Infect Dis 184 2001 405-409
11. J. Hoofnagle M. Ghany D. Kleiner E. Doo T. Heller K. Promrat et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin Hepatology 38 2003 66-74
12. N. Hiramatsu A. Kasahara F. Nakanishi T. Toyama M. Tsujii S. Tsuji et al. The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan Hepatol Res 29 2004 142-147
13. H. Ishida Y. Inoue J. Wong K. Okita Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: A Japanese trial Hepatol Res 28 2004 125-136
14. A. Tsubota H. Kumada Y. Arase K. Chayama S. Saitoh K. Ikeda et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: A randomized controlled trial in 170 patients Eur J Gastroenterol Hepatol 11 1999 1077-1083
15. F. Lirussi A. Beccarello L. Bortolato A. Morselli-Labate M. Crovatto S. Ceselli et al. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: Influence of HCV genotypes and severity of liver disease Liver 19 1999 381-388
16. S. Iino T. Tango T. Matsushima G. Toda K. Miyake K. Hino et al. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis Hepatol Res 19 2001 31-40
17. K. Miyake T. Tango Y. Ota K. Mitamura M. Yoshiba M. Kako et al. Efficacy of stronger neo-minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis J Gastroenterol Hepatol 17 2002 1198-1204